|
|
| Line 2: |
Line 2: |
|
| |
|
| {{CMG}}; {{AE}} {{S.M.}} | | {{CMG}}; {{AE}} {{S.M.}} |
| *[[Treatments|Treatment]] includes:<ref name="pmid31251395">{{cite journal| author=Huis In 't Veld EA, van Houdt WJ| title=Reply to Follow-up after treatment of dermatofibrosarcoma protuberans. | journal=Cancer | year= 2019 | volume= | issue= | pages= | pmid=31251395 | doi=10.1002/cncr.32341 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31251395 }} </ref><ref name="pmid16416612">{{cite journal| author=Loss L, Zeitouni NC| title=Management of scalp dermatofibrosarcoma protuberans. | journal=Dermatol Surg | year= 2005 | volume= 31 | issue= 11 Pt 1 | pages= 1428-33 | pmid=16416612 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16416612 }} </ref><ref name="pmid8646467">{{cite journal| author=Dawes KW, Hanke CW| title=Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. | journal=Dermatol Surg | year= 1996 | volume= 22 | issue= 6 | pages= 530-4 | pmid=8646467 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8646467 }} </ref><ref name="pmid10870053">{{cite journal| author=Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM et al.| title=Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. | journal=Cancer | year= 2000 | volume= 88 | issue= 12 | pages= 2711-20 | pmid=10870053 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10870053 }} </ref><ref name="pmid14983497">{{cite journal| author=DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK| title=Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. | journal=Cancer | year= 2004 | volume= 100 | issue= 5 | pages= 1008-16 | pmid=14983497 | doi=10.1002/cncr.20051 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14983497 }} </ref><ref name="pmid15221986">{{cite journal| author=Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB| title=Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. | journal=Cancer | year= 2004 | volume= 101 | issue= 1 | pages= 28-38 | pmid=15221986 | doi=10.1002/cncr.20316 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15221986 }} </ref>
| |
|
| |
|
| {| class="wikitable"
| | |
| |+Treatment options for dermatofibrosarcoma protuberans
| | |
| !style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Treatment option}}
| | |
| !style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Details}}
| | |
| |-
| | |
| |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Surgery]]'''
| | |
| |
| | |
| *[[Mohs micrographic surgery]]
| | |
| *[[Excision repair|Excisional]] [[surgery]] includes:
| |
| **Removal of [[subcutaneous fat]] (i.e. [[Wide and fast|wide]] [[local]] [[excision]] with 2 - 3 [[Centimetre|cm]] margins)
| |
| **3-[[Dimensional analysis|dimensional]] [[histological]] evaluation of margins (necessarily recommended in order to [[Prevention (medical)|prevent]] the [[tumor]] [[Recurrence plot|recurrence]])
| |
| |-
| |
| |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Targeted therapy|'''Targeted therapy''']]
| |
| |
| |
| * [[Imatinib]]-[[STI571]] ([[tyrosine kinase inhibitor]]) [[therapy]] (may be [[Effective method|effective]] in [[CD117]]- [[tumors]]) is the [[Gold standard (test)|gold standard]] [[Treatments|treatment]] of [[Recurrence plot|recurrent]] or [[inoperable]] [[tumor]]
| |
| * As [[imatinib]] [[Inhibition|inhibits]] [[PDGFB]], may be [[Effective method|effective]] for [[tumors]] positive for the t(17;22) [[Translocations|translocation]]
| |
| |-
| |
| |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Chemotherapy]]'''
| |
| |
| |
| * Less beneficial than [[targeted therapy]]
| |
| |-
| |
| |style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Radiotherapy]]'''
| |
| |
| |
| * May be required sometimes
| |
| |}
| |
|
| |
|
| ==Reference== | | ==Reference== |
| {{Reflist|2}} | | {{Reflist|2}} |